Curis Inc
Research Curis Inc (CRIS) on Bullrun: market cap USD 61.98M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerCRIS
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 61.98M
- Financial periodQ1 2026
- RevenueUSD 0
- Net income-USD 21.17M
- Free cash flow-USD 9.00M
Valuation Snapshot
latest market cap is USD 61.98M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 9.44M | -USD 7.58M | -USD 27.20M | 99.5% | -0.58 | USD 5.06M | USD 0 | USD 5.46M |
| FY2024 | USD 10.91M | -USD 43.39M | -USD 39.56M | 99.1% | -6.88 | USD 20.00M | USD 7.56M | -USD 6.00M |
| FY2023 | USD 10.02M | -USD 47.41M | -USD 38.43M | n/a | -8.96 | USD 26.68M | USD 8.50M | USD 19.67M |
| FY2022 | USD 10.16M | -USD 56.67M | -USD 54.75M | n/a | -12.14 | USD 19.66M | USD 4.46M | USD 46.55M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 61.98M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 12.80M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 25.97M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 75.15M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 2.65M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 21.81M | n/a | n/a | n/a |
About Curis Inc
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small-molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single-arm expansion trial in patients with relapsed/refractory primary central nervous system lymphoma.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Curis Inc's market cap?
Curis Inc's market capitalization is USD 61.98M.
What does Curis Inc do?
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small-molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single-arm expansion trial in patients with relapsed/refractory primary central nervous system lymphoma.